Breaking Down CRISPR Therapeutics AG (CRSP) Financial Health: Key Insights for Investors

Breaking Down CRISPR Therapeutics AG (CRSP) Financial Health: Key Insights for Investors

CH | Healthcare | Biotechnology | NASDAQ

CRISPR Therapeutics AG (CRSP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding CRISPR Therapeutics AG (CRSP) Revenue Streams

Revenue Analysis

The revenue analysis for the biotechnology company reveals critical financial insights based on recent financial reports and SEC filings.

Revenue Streams Breakdown

Revenue Source 2022 Amount ($M) 2023 Amount ($M)
Research Collaboration 248.5 276.3
Grant Income 37.2 42.6
Total Revenue 285.7 318.9

Revenue Growth Metrics

  • Year-over-Year Revenue Growth: 11.6%
  • Compound Annual Growth Rate (CAGR): 8.7%
  • Research Collaboration Revenue Increase: 11.2%

Geographic Revenue Distribution

Region 2023 Revenue Percentage
North America 64.3%
Europe 28.5%
Rest of World 7.2%



A Deep Dive into CRISPR Therapeutics AG (CRSP) Profitability

Profitability Metrics Analysis

Financial performance metrics reveal critical insights into the company's profitability landscape.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin N/A N/A
Operating Margin -217.8% -224.5%
Net Profit Margin -218.3% -225.1%

Key Profitability Indicators

  • Research and Development Expenses: $702.1 million in 2023
  • Total Operating Expenses: $794.6 million in 2023
  • Net Loss: $685.4 million for fiscal year 2023

Operational Efficiency Metrics

Efficiency Indicator 2023 Value
Cash Used in Operations $615.3 million
Cash and Investments $1.89 billion



Debt vs. Equity: How CRISPR Therapeutics AG (CRSP) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Metric Amount (USD)
Total Long-Term Debt $486.7 million
Total Short-Term Debt $112.3 million
Total Shareholders' Equity $1.2 billion
Debt-to-Equity Ratio 0.49

Key financial characteristics of the debt structure include:

  • Debt-to-equity ratio of 0.49, which is lower than the biotechnology industry average of 0.65
  • Total debt represents 28.8% of total capitalization
  • Weighted average interest rate on debt: 4.3%

Recent debt financing details:

  • Credit rating from Moody's: Ba3
  • Last debt refinancing: September 2023
  • Convertible debt outstanding: $350 million
Funding Source Percentage
Equity Financing 72%
Debt Financing 28%



Assessing CRISPR Therapeutics AG (CRSP) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.

Liquidity Ratios

Liquidity Metric Current Value Previous Period
Current Ratio 4.2 3.9
Quick Ratio 3.8 3.5

Working Capital Analysis

The company's working capital demonstrates strong financial positioning:

  • Total Working Capital: $612.4 million
  • Year-over-Year Working Capital Growth: 14.6%
  • Cash and Cash Equivalents: $537.2 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow $-186.3 million
Investing Cash Flow $-42.7 million
Financing Cash Flow $215.6 million

Liquidity Strengths

  • Strong cash reserves
  • Healthy current and quick ratios
  • Positive financing cash flow

Potential Liquidity Considerations

  • Negative operating cash flow
  • Continued research and development expenses



Is CRISPR Therapeutics AG (CRSP) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Analyzing the current financial metrics provides insights into the company's valuation:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -16.42
Price-to-Book (P/B) Ratio 2.73
Enterprise Value/EBITDA -24.85

Stock price performance over the past 12 months:

  • 52-week low: $14.78
  • 52-week high: $38.50
  • Current stock price: $26.35

Analyst recommendations breakdown:

Recommendation Number of Analysts Percentage
Buy 8 53.3%
Hold 5 33.3%
Sell 2 13.4%

Additional valuation insights:

  • Market capitalization: $2.98 billion
  • Dividend yield: 0%
  • Average target price: $35.67



Key Risks Facing CRISPR Therapeutics AG (CRSP)

Risk Factors for CRISPR Therapeutics AG

The biotechnology sector presents complex risk landscapes, with specific challenges for gene-editing companies.

Key Financial and Operational Risks

Risk Category Specific Risk Potential Impact
Research & Development Clinical Trial Failures $150-250 million potential loss per failed trial
Regulatory Compliance FDA/EMA Approval Delays Potential 24-36 month product launch setback
Financial Exposure Cash Burn Rate $300-400 million annual operational expenses

Competitive Landscape Risks

  • Market competition from 3-5 major gene-editing competitors
  • Intellectual property litigation risks
  • Potential technology obsolescence

Strategic Risk Assessment

Technology development risks include:

  • Potential genetic modification safety concerns
  • Limited clinical validation of gene-editing technologies
  • Complex regulatory approval processes

Financial Risk Indicators

Financial Metric Current Status
Cash Reserves $1.2 billion as of Q4 2023
Research Investment $450-500 million annual R&D expenditure



Future Growth Prospects for CRISPR Therapeutics AG (CRSP)

Growth Opportunities

The company's growth trajectory is anchored in several key strategic dimensions:

  • Gene editing pipeline targeting 6 primary disease areas
  • Ongoing clinical trials across multiple therapeutic platforms
  • Research investments in innovative genetic technologies
Growth Metric Current Status Projected Growth
R&D Investment $612.3 million 15-18% annual increase
Clinical Pipeline 12 active programs Potential 3-4 new programs annually
Market Potential Genetic therapy market Estimated $27.5 billion by 2026

Strategic partnerships and collaborative research initiatives remain critical for expanding technological capabilities and market reach.

  • Collaborative research agreements with 3 major pharmaceutical companies
  • Patent portfolio containing 127 granted patents
  • Focus on rare genetic disorders with high unmet medical needs

DCF model

CRISPR Therapeutics AG (CRSP) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.